Latest Tempus News & Updates

See the latest news and media coverage for Tempus. We track all announcements, press releases, and industry mentions in real time, all in one place.

Tempus

AI-enabled precision medicine platform

tempus.com

Headquarters: Chicago, United States
Founded year: 2015
Company type: Public company
Number of employees: 3,000–5,000

Last updated Today

Latest news about Tempus

In short: Tempus AI reported a 36.1% revenue surge, secured key FDA approvals for its genomic assays, and expanded its strategic oncology partnerships.

Company announcements

June 3 Tempus

Tempus launches open-source digital pathology consortium with founding members

The consortium aims to democratize digital pathology by open-sourcing the Paige IMS platform, slide viewer, case management, and AI modules.

May 31 Tempus

Tempus launches next-generation Lens AI platform for drug development

The platform connects multimodal data, AI tooling, and computational infrastructure to accelerate oncology drug research and development.

May 30 Tempus

Tempus launches the PRECISION Challenge for oncology research

The program provides data, funding, and compute to researchers for breakthroughs using foundation models.

May 29 Tempus

Tempus announces initial results from its multimodal foundation model efforts

The model demonstrated predictive accuracy and survival stratification in NSCLC patients, and showed utility for drug development.

Media coverage

June 15 Yahoo Finance

Cathie Wood buys $529.7 million of popular new stock

Cathie Wood, head of Ark Investment Management, has a history of buying stocks shortly after their IPOs. In recent years, Wood’s Ark funds have invested...

June 13 Yahoo Finance

Tempus AI (TEM) Stock After 23% Year-To-Date Decline Is Opportunity Emerging

Wondering if Tempus AI at around US$47.82 is starting to look interesting, or if the stock still...

June 11 GuruFocus

Tempus AI (TEM) Achieves Major Milestone with ECG Software Valid

On June 11, 2026, Tempus AI Inc. (TEM) announced a significant advancement following the publication of a multi-site validation study for its software, which ob...

June 5 The Globe and Mail

Guggenheim Reaffirms Their Buy Rating on Tempus AI, Inc. Class A (TEM)

In a report released today, Subbu Nambi from Guggenheim maintained a Buy rating on Tempus AI, Inc. Class A, with a price target of $60.00...

Never miss news about Tempus

Track Tempus and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Tempus competitors & trending companies

Browse news for competitors to Tempus and other trending companies.